Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

Erasca, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN DIEGO, SEPT. 02, 2025 (GLOBE NEWSWIRE) -- ERASCA, INC.(NASDAQ: ERAS), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY SINGULARLY FOCUSED ON DISCOVERING, DEVELOPING, AND COMMERCIALIZING THERAPIES FOR PATIENTS WITH RAS/MAPK PATHWAY-DRIVEN CANCERS, TODAY ANNOUNCED ITS PARTICIPATION IN THEMORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE BEING HELD AT THESHERATON NEW YORK TIMES SQUARE IN NEW YORK, NY.

ERASCA TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE

EFFICIENT EXECUTION ACCELERATED CLINICAL ENTRY OF PAN-RAS MOLECULAR GLUEERAS-0015 AND PAN-KRAS INHIBITOR ERAS-4001 PHASE 1 MONOTHERAPY DATA FOR RAS-TARGETING FRANCHISE EXPECTED IN 2026 ROBUST BALANCE SHEET WITH CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF$387 MILLIONAS OFJUNE 30, 2025 IS EXPECTED TO FUND OPERATIONS INTO H2 2028 SAN DIEGO, AUG. 12, 2025 (GLOBE NEWSWIRE) -- ERASCA, INC. (NASDAQ: ERAS), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY SINGULARLY FOCUSED ON DISCOVERING, DEVELOPING, AND COMMERCIALIZING THERAPIES FOR PATIENTS WITH RAS/MAPK PATHWAY-DRIVEN CANCERS, TODAY PROVIDED BUSINESS UPDATES AND REPORTED FINANCIAL RESULTS FOR THE FISCAL QUARTER ENDEDJUNE 30, 2025. WE ARE EXCITED BY THE CONTINUED MOMENTUM OF OUR RAS-TARGETING FRANCHISE, INCLUDING ITS EARLY ADVANCEMENT INTO THE CLINIC, WHICH HAS BROAD APPLICATION IN MULTIPLE AREAS OF HIGH UNMET MEDICAL NEED, SAID JONATHAN E.

ERASCA REPORTS SECOND QUARTER 2025 BUSINESS UPDATES AND FINANCIAL RESULTS

BOTH ERAS-4001 AND POTENTIAL BEST-IN-CLASS PAN-RAS MOLECULAR GLUE ERAS-0015 RECEIVED IND CLEARANCE IN MAY AHEAD OF COMPANY GUIDANCE INITIAL PHASE 1 MONOTHERAPY DATA FOR BOTH RAS-TARGETING PROGRAMS EXPECTED IN 2026 SAN DIEGO, JUNE 02, 2025 (GLOBE NEWSWIRE) -- ERASCA, INC. (NASDAQ: ERAS), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY SINGULARLY FOCUSED ON DISCOVERING, DEVELOPING, AND COMMERCIALIZING THERAPIES FOR PATIENTS WITH RAS/MAPK PATHWAY-DRIVEN CANCERS, TODAY ANNOUNCED CLEARANCE OF AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) FOR ERAS-4001, A POTENTIAL FIRST-IN-CLASS AND BEST-IN-CLASS PAN-KRAS INHIBITOR, FOR THE TREATMENT OF PATIENTS WITH KRAS-MUTANT (KRASM) SOLID TUMORS. OUR RAS-TARGETING FRANCHISE CONTINUES TO MEANINGFULLY ADVANCE, AND NOW WITH CLEARANCE OF OUR IND FOR ERAS-4001, WE ARE EXCITED TO ADVANCE BOTH ERAS-4001 AND ERAS-0015 INTO THE CLINIC AHEAD OF OUR GUIDANCE, SAID JONATHAN E.

ERASCA ANNOUNCES IND CLEARANCE FOR POTENTIAL FIRST-IN-CLASS AND BEST-IN-CLASS PAN-KRAS INHIBITOR ERAS-4001

SAN DIEGO, MAY 29, 2025 (GLOBE NEWSWIRE) -- ERASCA, INC.(NASDAQ: ERAS), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY SINGULARLY FOCUSED ON DISCOVERING, DEVELOPING, AND COMMERCIALIZING THERAPIES FOR PATIENTS WITH RAS/MAPK PATHWAY-DRIVEN CANCERS, TODAY ANNOUNCED THATMANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES IN JUNE 2025 AND WILL ALSO PARTICIPATE IN ONE-ON-ONE INVESTOR MEETINGS AT EACH OF THESE CONFERENCES.

ERASCA TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN JUNE

EARLY ENTRY OF RAS-TARGETING FRANCHISE INTO CLINIC ENABLED BY STRONG EXECUTION INITIAL PHASE 1 MONOTHERAPY DATA FOR PAN-RAS MOLECULAR GLUEERAS-0015 AND PAN-KRAS INHIBITOR ERAS-4001 EXPECTED IN 2026 ROBUST BALANCE SHEET WITH CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF$411 MILLIONAS OFMARCH 31, 2025 WITH CASH RUNWAY GUIDANCE EXTENDED TO H2 2028 SAN DIEGO, MAY 13, 2025 (GLOBE NEWSWIRE) -- ERASCA, INC. (NASDAQ: ERAS), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY SINGULARLY FOCUSED ON DISCOVERING, DEVELOPING, AND COMMERCIALIZING THERAPIES FOR PATIENTS WITH RAS/MAPK PATHWAY-DRIVEN CANCERS, TODAY PROVIDED BUSINESS UPDATES AND REPORTED FINANCIAL RESULTS FOR THE FISCAL QUARTER ENDEDMARCH 31, 2025. WE ARE PLEASED WITH THE PACE AND EXECUTION OF OUR RAS-TARGETING FRANCHISE AND ITS EARLY ENTRY INTO THE CLINIC FOLLOWING THE RECENT IND CLEARANCE FOR ERAS-0015 AND IND FILING FOR ERAS-4001, SAID JONATHAN E.

ERASCA REPORTS FIRST QUARTER 2025 BUSINESS UPDATES AND FINANCIAL RESULTS

IND CLEARED FOR PAN-RAS MOLECULAR GLUE ERAS-0015 AND IND SUBMITTED FOR PAN-KRAS INHIBITOR ERAS-4001, BOTH AHEAD OF SCHEDULE; PHASE 1 MONOTHERAPY DATA FOR BOTH PROGRAMS EXPECTED IN 2026 MEANINGFUL EXTENSION OF CASH RUNWAY GUIDANCE FROM H2 2027 TO H2 2028 FOLLOWING STRATEGIC DECISION TO PURSUE PARTNERSHIP OPPORTUNITIES FOR NAPORAFENIB SAN DIEGO, MAY 13, 2025 (GLOBE NEWSWIRE) -- ERASCA, INC. (NASDAQ: ERAS), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY SINGULARLY FOCUSED ON DISCOVERING, DEVELOPING, AND COMMERCIALIZING THERAPIES FOR PATIENTS WITH RAS/MAPK PATHWAY-DRIVEN CANCERS, TODAY ANNOUNCED CLEARANCE OF AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) FOR ERAS-0015, A PAN-RAS MOLECULAR GLUE WITH BEST-IN-CLASS POTENTIAL FOR PATIENTS WITH RAS-MUTANT (RASM) SOLID TUMORS, AND SUBMISSION OF AN IND APPLICATION FOR ERAS-4001, A POTENTIAL FIRST-IN-CLASS PAN-KRAS INHIBITOR IN KRAS-MUTANT (KRASM) SOLID TUMORS. THE COMPANY ALSO ANNOUNCED A STRATEGIC DECISION TO PURSUE PARTNERSHIP OPPORTUNITIES FOR NAPORAFENIB, ENABLING A MEANINGFUL EXTENSION OF CASH RUNWAY GUIDANCE FROM THE SECOND HALF OF 2027 TO THE SECOND HALF OF 2028.

ERASCA ANNOUNCES EARLY CLINICAL ADVANCEMENT AND PRIORITIZATION OF RAS-TARGETING FRANCHISE COUPLED WITH MORE THAN 3 YEARS OF PROJECTED CASH RUNWAY

SAN DIEGO, MAY 07, 2025 (GLOBE NEWSWIRE) -- ERASCA, INC.(NASDAQ: ERAS), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY SINGULARLY FOCUSED ON DISCOVERING, DEVELOPING, AND COMMERCIALIZING THERAPIES FOR PATIENTS WITH RAS/MAPK PATHWAY-DRIVEN CANCERS, TODAY ANNOUNCED ITS PARTICIPATION IN THEBANK OF AMERICA SECURITIES 2025 HEALTH CARE CONFERENCE BEING HELD AT THEENCORE HOTEL INLAS VEGAS, NEVADA. MANAGEMENT WILL PRESENT ONWEDNESDAY, MAY 14, 2025, AT2:35 PM PACIFIC TIMEAND WILL ALSO PARTICIPATE IN ONE-ON-ONE INVESTOR MEETINGS.

ERASCA TO PRESENT AT THE BANK OF AMERICA SECURITIES HEALTH CARE CONFERENCE

ERAS-0015 AND ERAS-4001 SHOWED ROBUST ANTI-TUMOR ACTIVITY AS MONOTHERAPY AND COMBINATION THERAPY FIRST-IN-CLASS EXAMPLES OF DIRECT SHOC2 BINDERS AND MODULATORS OF SMP COMPLEX ASSEMBLY IDENTIFIED WITH POTENTIAL TO BLOCK ONCOGENIC RAS/MAPK PATHWAY SIGNALING SAN DIEGO, APRIL 29, 2025 (GLOBE NEWSWIRE) -- ERASCA, INC. (NASDAQ: ERAS), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY SINGULARLY FOCUSED ON DISCOVERING, DEVELOPING, AND COMMERCIALIZING THERAPIES FOR PATIENTS WITH RAS/MAPK PATHWAY-DRIVEN CANCERS, TODAY PRESENTED NEW PRECLINICAL DATA REINFORCING THE BEST-IN-CLASS PROFILES OF ERASCA'S RAS-TARGETING FRANCHISE AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING IN CHICAGO, ILLINOIS. THE COMPANY ALSO PRESENTED POTENTIAL FIRST-IN-CLASS EXAMPLES OF DIRECT SHOC2 BINDERS AND MODULATORS OF SMP COMPLEX ASSEMBLY, REPRESENTING A NEW APPROACH TO BLOCK ONCOGENIC RAS/MAPK PATHWAY SIGNALING.

ERASCA PRESENTS NEW PRECLINICAL DATA REINFORCING BEST-IN-CLASS POTENTIAL OF RAS-TARGETING FRANCHISE AT THE 2025 AACR ANNUAL MEETING

PRESENTATIONS WILL FEATURE POTENTIAL BEST-IN-CLASS PAN-RAS MOLECULAR GLUE ERAS-0015 AND PAN-KRAS INHIBITOR ERAS-4001 ERASCA WILL ALSO PRESENT POTENTIAL FIRST-IN-CLASS EXAMPLES OF DIRECT SMP COMPLEX INHIBITORS, REPRESENTING A NEW APPROACH TO BLOCK THE RAS/MAPK PATHWAY SAN DIEGO, MARCH 25, 2025 (GLOBE NEWSWIRE) -- ERASCA, INC. (NASDAQ: ERAS), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY SINGULARLY FOCUSED ON DISCOVERING, DEVELOPING, AND COMMERCIALIZING THERAPIES FOR PATIENTS WITH RAS/MAPK PATHWAY-DRIVEN CANCERS, TODAY ANNOUNCED THE COMPANY WILL PRESENT THREE POSTER PRESENTATIONS AT THE UPCOMING AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING, TAKING PLACE APRIL 25 - 30, 2025, IN CHICAGO, ILLINOIS. THE ABSTRACTS WILL BE AVAILABLE ON THE AACR 2025 MEETING WEBSITE.

ERASCA ANNOUNCES THREE POSTER PRESENTATIONS AT THE 2025 AACR ANNUAL MEETING

POTENTIALLY BEST-IN-CLASS RAS-TARGETING FRANCHISE ADVANCING WITH BOTH ERAS-0015 AND ERAS-4001 EXPECTED TO ENTER THE CLINIC IN 2025

Erasca, Inc.

ERAS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Erasca, Inc.

ERAS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ERAS